Published in J Virol on November 12, 2014
Human Adaptation of Ebola Virus during the West African Outbreak. Cell (2016) 1.41
Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ (2015) 1.00
Soluble Glycoprotein Is Not Required for Ebola Virus Virulence in Guinea Pigs. J Infect Dis (2015) 0.78
Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. J Gen Virol (2016) 0.78
Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. J Biol Chem (2017) 0.75
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother (2015) 0.75
Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci Rep (2017) 0.75
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Ebola haemorrhagic fever. Lancet (2011) 8.28
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (2005) 7.07
The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A (1996) 7.02
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology (1995) 5.34
A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A (2000) 5.30
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol (2002) 4.47
Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A (2009) 4.38
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A (1998) 4.33
Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol (2006) 4.24
Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature (2011) 3.66
Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science (2001) 3.08
Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol (2002) 3.06
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol (2004) 2.92
Covalent modifications of the ebola virus glycoprotein. J Virol (2002) 2.84
Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog (2010) 2.60
Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog (2010) 2.60
Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annu Rev Genet (1998) 2.42
Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol (2004) 2.34
Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology (2000) 2.33
Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J Infect Dis (2011) 2.30
The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett (1992) 2.24
Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol (2007) 2.16
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol (2001) 2.13
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J (2012) 2.08
Few and far between: how HIV may be evading antibody avidity. PLoS Pathog (2010) 1.94
Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol (2007) 1.93
BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol (2010) 1.82
Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J (2004) 1.73
Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol (2005) 1.61
How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol (2007) 1.52
Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol (2005) 1.44
Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog (2010) 1.29
The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis. Traffic (2000) 1.28
Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J (2006) 1.28
Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. J Virol (2000) 1.28
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol (2009) 1.23
Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J Virol (2010) 1.18
Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol (2006) 1.17
Attenuation of bunyavirus replication by rearrangement of viral coding and noncoding sequences. J Virol (2005) 1.16
The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol (2006) 1.15
Filovirus entry into cells - new insights. Curr Opin Virol (2012) 1.14
Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology (2008) 1.14
Establishment and application of an infectious virus-like particle system for Marburg virus. J Gen Virol (2010) 1.11
The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis (2011) 1.10
The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol (2012) 1.09
The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J Virol (2006) 1.09
A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08
Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils. J Immunol (2000) 1.07
Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. Virology (2005) 0.96
Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein. J Virol (2000) 0.88
Ultraviolet radiation-induced transcription is associated with gene-specific histone acetylation. Photochem Photobiol (2008) 0.88
Evolutionary conservation of the membrane fusion machine. IUBMB Life (1999) 0.83